By: IPP Bureau
Last updated : May 11, 2026 8:05 am
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Bajaj Healthcare Limited reported a 12.6 percent year-on-year increase in revenue from operations for FY26 at Rs 6,110.3 million, supported by strong growth in API exports and formulations business.
The company’s EBITDA for FY26 rose 9.9 percent to Rs 1,119.5 million, while Profit After Tax (PAT) from continuing operations before exceptional items increased 27.1 percent to Rs 545.6 million. PAT margin improved to 8.8 percent compared to 7.9 percent in FY25.
During Q4 FY26, revenue from operations remained largely stable at Rs 1,530.6 million, while EBITDA grew marginally by 1.2 percent to Rs 256.3 million. PAT from continuing operations before exceptional items increased 19.3 percent year-on-year to Rs 138.3 million.
The company’s API exports business emerged as a major growth driver, rising 51.6 percent year-on-year to Rs 1,881.4 million in FY26, aided by demand from regulated markets including Europe, the UK, and Latin America. The formulations business also recorded 12.6 percent growth during the year.
On the product development front, Bajaj Healthcare said its novel anti-epileptic molecule Cenobamate is progressing through Phase III clinical trials and is expected to launch in Q2 FY27. The company also completed the bioequivalence study for Suvorexant tablets and plans to file an application with the DCGI shortly.
The company filed 41 Drug Master Files (DMFs) during Q4, taking its cumulative filings to 110, further strengthening its global regulatory presence.
Commenting on the performance, Anil Jain, Managing Director of Bajaj Healthcare, said the company navigated a challenging operating environment marked by domestic API price erosion and geopolitical disruptions in West Asia. He added that operational discipline, export growth, and diversification into formulations and CDMO business supported profitability improvement during the year.
The company also announced the conversion of over 2 million warrants into equity shares during the quarter, raising additional capital of Rs 527 million to support future growth initiatives.